Aspirin prophylaxis for vascular disease

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.

PURPOSE Clopidogrel is more effective than aspirin in preventing recurrent vascular events, but concerns about its cost-effectiveness have limited its use. We evaluated the cost-effectiveness of clopidogrel and aspirin as secondary prevention in patients with a prior myocardial infarction, a prior stroke, or peripheral arterial disease. METHODS We constructed Markov models assuming a societal...

Rapid health impact assessment of aspirin promotion for the secondary prophylaxis of vascular events in Wales.

BACKGROUND Evidence from two surveys in Wales, one of the countries of the United Kingdom, shows that there is an under-use of aspirin for secondary prophylaxis. A rapid health impact assessment of a policy of aspirin promotion in Wales is undertaken, with some estimates on service provision. METHODS In this analysis, a general population approach rather than gender-specific calculations was...

Who should take aspirin for primary prophylaxis of coronary heart disease?

Aspirin prophylaxis and the prevalence of anaemia.

BACKGROUND Anaemia and vascular disease are both common amongst the elderly and frequently co-exist. Whilst a consensus exists concerning the benefits of low-dose aspirin in reducing risk from atheromatous disease, nonetheless concerns arise in view of its harmful effect on gastric mucosa and its influence upon haemostasis, with the possibility of subsequent gastrointestinal bleeding. This stud...

Ethical considerations in relation to aspirin prophylaxis.

Low-dose aspirin prophylaxis, 75-150 mg per day, reduces the risk of vascular events and there is also promising evidence that it may also reduce the risk of cancer. Increased use of aspirin may confer considerable benefits to the population, but the risk of causing a gastric bleed is certainly a major concern. There are ethical considerations related to the potential increased use of aspirin i...